Summary: Amgen's pipeline includes 12 drugs in Phase 3, 8 in Phase 2, and 5 in Phase 1. Key assets include Tezspire (asthma), Lumakras (NSCLC), and AMG 133 (obesity). Recent progress: Tezspire filed for FDA approval in Q1 2026.
| Drug |
Indication |
Sponsor |
Phase |
Progress |
| Tezspire |
Asthma |
Amgen |
FDA Filing |
|
| Lumakras |
NSCLC |
Amgen |
Phase 3 |
|
| AMG 133 |
Obesity |
Amgen |
Phase 2 |
|
| AMG 160 |
Prostate Cancer |
Amgen |
Phase 1 |
|
- Tezspire filed NDA with FDA (Q1 2026)
- Lumakras Phase 3 data published (Jan 2026)
- AMG 133 Phase 2 enrollment completed
- AMG 160 first patient dosed (Dec 2025)
- Phase 3: 12 drugs
- Phase 2: 8 drugs
- Phase 1: 5 drugs
- Preclinical: 20 assets